List of Janumet Xr drug patents
Janumet Xr is owned by Merck Sharp Dohme.
Janumet Xr contains Metformin Hydrochloride; Sitagliptin Phosphate.
Janumet Xr has a total of 6 drug patents out of which 4 drug patents have expired.
Expired drug patents of Janumet Xr are:
- US7125873
- US6699871*PED
- US7125873*PED
- US6699871
Janumet Xr was authorised for market use on 02 February, 2012.
Janumet Xr is available in tablet, extended release;oral dosage forms.
Janumet Xr can be used as method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate.
The generics of Janumet Xr are possible to be released after 24 May, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(8 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(8 months ago) | |
|
US6699871
(Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(a month ago) | |
|
US7125873
(Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(a month ago) | |
|
US7326708
(Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
JANUMET XR family patents
14
United States
5
Norway
5
Germany
5
European Union
3
Israel
3
Denmark
3
Austria
3
Argentina
3
Portugal
3
Spain
3
Korea, Republic of
3
Iceland
3
China
3
Georgia
3
EA
2
South Africa
2
Mexico
2
Australia
2
Hong Kong
2
Slovenia
2
Jordan
2
Hungary
2
Morocco
2
Costa Rica
2
Croatia
2
Brazil
2
Cyprus
2
Yugoslavia
2
Malaysia
2
Netherlands
2
Peru
2
Dominican Republic
2
Poland
2
Taiwan, Province of China
2
Ecuador
2
Luxembourg
2
Ukraine
2
Japan
2
Canada
2
New Zealand
2
ME
1
Lithuania
1
Belgium
1
Colombia
1
Bulgaria
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic